ArticleThe Journal of antimicrobial chemotherapy2025
Results from the Survey of Antibiotic Resistance (SOAR) 2020-21 in Vietnam: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidence of Cefotaxime-Resistant Haemophilus influenzae Is Linked to Regional Consumption of Oral Aminopenicillins and Parenteral Third-Generation Cephalosporins in Norway.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesAntibiotic susceptibility determination of Streptococcus pneumoniae and Haemophilus influenzae from community-acquired respiratory infections collected in 2020-21 from two hospitals in Ho Chi Minh City, Vietnam.
methodsMICs were determined by CLSI broth microdilution; susceptibility was interpreted based on CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
resultsA total of 144 S. pneumoniae and 191 H. influenzae isolates were collected. S. pneumoniae susceptibility to amoxicillin and amoxicillin/clavulanic acid (2:1) was 56.9% and 56.3% (CLSI), 29.2% and 25.7% (EUCAST high-dose) and 78.5% using high-dose amoxicillin (4 g/0.25 g/day, PK/PD). Susceptibility to ceftriaxone was 91.7% by EUCAST (high-dose) and 50.7% by CLSI or PK/PD. Pneumococcal cefotaxime susceptibility was 61.8% by CLSI (29.9%, EUCAST). Penicillin susceptibility was 69.4% by CLSI intravenous/EUCAST high-dose, but 6.3% using CLSI oral/EUCAST low-dose breakpoints. Tetracyclines, macrolides and trimethoprim/sulfamethoxazole had 5.6%-16.7% susceptibility.Among H. influenzae isolates, 59.7% were β-lactamase-negative, of which 87.7% and 74.6% were ampicillin-resistant (BLNAR) following EUCAST and CLSI criteria, respectively. H. influenzae fluoroquinolone, macrolide and tetracycline susceptibility reached 62.0%-89.5% (CLSI, EUCAST); macrolide susceptibility was 3.7%-5.8% (PK/PD). All were susceptible to ceftriaxone (all breakpoints) and cefotaxime (CLSI, PK/PD); cefotaxime susceptibility was 15.7% by EUCAST. H. influenzae amoxicillin/clavulanic acid susceptibility was 45.5% (EUCAST) and 32.5% (CLSI) but increased to 82.8% with high-dose (4 g/0.25 g/day, PK/PD).
conclusionsThe hospitals showed high rates of penicillin-resistant S. pneumoniae and BLNAR H. influenzae. S. pneumoniae showed low susceptibility to macrolides and several cephalosporins. H. influenzae fluoroquinolone susceptibility was 88.0%-89.0% (CLSI). Future surveillance across Vietnam will help understand susceptibility trends over time and regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.